<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81558">
  <stage>Registered</stage>
  <submitdate>22/08/2006</submitdate>
  <approvaldate>18/01/2007</approvaldate>
  <actrnumber>ACTRN12607000058471</actrnumber>
  <trial_identification>
    <studytitle>The acceptability, safety and tolerability of combined methadone-naloxone - Intra muscular (IM) challenge</studytitle>
    <scientifictitle>Does intra muscular methadone nalxone in a 50:1 ratio precipitate withdrawal among opioid dependent individuals</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Opioid dependence</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants receive 3 injections:
IM Saline adminsitered at baseline, 10mg/.2mg methadone naloxone administered IM at 20 minutes and if no objective signs of withdrawal are observed at 50 minutes, a further 20mg/.4mg methadone naloxone administered IM.</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Opioid Withdrawal Score (OOWS)</outcome>
      <timepoint>At 5, 15, 30 and 60 minutes</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pupil size (mm) </outcome>
      <timepoint>At 5, 15, 30 and 60 minutes</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Subjective Opioid Withdrawal Score (SOWS)</outcome>
      <timepoint>At 5, 15, 30 and 60 minutes</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Profile of Mood States (POMS) Score</outcome>
      <timepoint>At 5, 15, 30 and 60 minutes</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Morphine Benzedrine Group (MBG) Score</outcome>
      <timepoint>At 5, 15, 30 and 60 minutes</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Opioid dependent; in treatment for &gt;2mths; on methadone dose of &gt;20mg; stabilised on current dose for &gt;4 weeks; Able to provide voluntary informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Considered unwilling, unable or unlikely to comply with the study protocol;Lactating and pregnant women; Active psychotic illness.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>24/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>5</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Langton Centre</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Biomed Pty Ltd</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Biomed Pty Ltd</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to test whether intramuscualr methadone-naloxone in a 50:1 ratio precipitates withdrawal in opioid dependent individuals.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Langton Centre approved By SESIAHS HREC</ethicname>
      <ethicaddress />
      <ethicapprovaldate>25/10/2005</ethicapprovaldate>
      <hrec>05/270</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Anni Ryan</name>
      <address>591 South Dowling Street
Surry Hills NSW 2010</address>
      <phone>+61 2 93328777</phone>
      <fax>+61 2 93328700</fax>
      <email>Anni.Ryan@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor James Bell</name>
      <address>591 South Dowling Street
Surry Hills NSW 2010</address>
      <phone>+61 2 93328777</phone>
      <fax>+61 2 93328700</fax>
      <email>James.Bell@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>